1 hour ago
3
Prosper Junior Bakiny, The Motley Fool
Tue, June 16, 2026 astatine 5:35 AM CDT 6 min read
Investing successful dividend stocks is simply a large mode to gain superior returns implicit the agelong run. How bash we cognize that? According to immoderate research, astir of the S&P 500's returns implicit the past respective decades tin beryllium attributed to reinvested dividends and compounding. This information makes a beardown lawsuit for dividend investing. However, buying shares successful conscionable immoderate aged institution that happens to wage dividends isn't the mode to go: They aren't each created equal. With that said, let's see 3 fantabulous dividend stocks that are worthy investors' hard-earned cash: Bristol Myers Squibb (NYSE: BMY), Merck (NYSE: MRK), and Medtronic (NYSE: MDT). Here's wherefore these 3 income stocks are worthy sticking with for the agelong term.
Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »
1. Bristol Myers Squibb
Bristol Myers is simply a starring pharmaceutical institution with a heavy portfolio of medicines spanning galore therapeutic areas, peculiarly oncology. The drugmaker typically generates decent gross and earnings, though it has encountered challenges successful caller years owed to patent cliffs. Bristol Myers is bouncing back, though. Newer approvals are helping propulsion income successful the close direction. The company's first-quarter gross climbed by 3% twelvemonth implicit twelvemonth to $11.5 billion.
Bristol Myers' maturation portfolio -- composed of newer medicines that won't brushwood patent cliffs anytime soon -- posted adjacent stronger growth. Its income were $6.2 billion, 12% higher than the year-ago period. These newer medicines should relationship for a larger percent of Bristol Myers' apical enactment wrong a fewer years and assistance income maturation adjacent higher. And portion determination are different patent cliffs connected the skyline -- peculiarly that of Bristol Myers' anticoagulant, Eliquis -- the drugmaker has a heavy pipeline of promising candidates that should assistance it flooded them.
In fact, 1 of Bristol Myers' astir breathtaking pipeline assets is simply a imaginable successor to Eliquis called milvexian. Bristol Myers thinks this medicine has multibillion-dollar potential, partially due to the fact that it could debar 1 cardinal drawback of accepted anticoagulants: Bleeding risk. Bristol Myers has plentifulness of different candidates beyond this one. Over the agelong run, it should win successful processing newer and amended products portion increasing its income and net astatine a decent clip.
English (CA) · 
English (US) · 
Spanish (MX) ·